XTL Biopharmaceuticals Completes Transformative Psyga Bio Acquisition and $1.5M Private Placement
XTLB sits 42% above its 52-week low of $2.01.
Summary
XTL Biopharmaceuticals has finalized its acquisition of Psyga Bio, pivoting its core business to psychedelic medicine, and simultaneously closed a $1.5 million private placement to fund its new strategy.
Key Events · M&A and Partnerships · XTLB
-
Acquisition Consummated
XTL Biopharmaceuticals completed the acquisition of approximately 83.40% of Psyga Bio Ltd., an Israeli advanced biotechnology company focused on psychedelic and functional mushrooms.
-
Strategic Business Pivot
The acquisition transforms XTL into a dedicated psychedelic medicine company, leveraging Psyga Bio's clinical pipeline, licensed GMP manufacturing facility, and unique intellectual property library.
-
Significant Dilution from Acquisition
XTL issued American Depositary Shares (ADSs) representing approximately 33.36% of its post-issuance capital to Psyga Bio shareholders, with potential for an additional 25% based on clinical and commercial milestones.
-
$1.5 Million Private Placement Closed
A private placement of US$1,500,000 was completed at a purchase price of US$2.70 per ADS, including warrants, providing critical funding for the new operations.
Analysis · XTLB · Life Sciences
This filing confirms the closing of a major acquisition that fundamentally transforms XTL into a psychedelic biotechnology company. Concurrently, the company completed a $1.5 million private placement, which, while highly dilutive, provides essential capital to fund the new strategic direction and address previous financial and compliance challenges. This marks a definitive step in the company's efforts to secure its future and maintain its Nasdaq listing.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XTLB was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $2.01 to $10.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.